Phase i studies with baker's antifol (baf) (nsc 139105)

Victorio Rodriguez, Jeffrey Gottlieb, Michael A. Burgess, Robert Livingston, Warren Wheeler, Gary Spitzer, Gerald P. Bodey, George R. Blumenschein, Emil J. Freireich

Research output: Contribution to journalArticlepeer-review

10 Scopus citations


Phase I studies were conducted in 58 adult cancer patients with Baker's Antifol (BAF), a new active‐site directed inhibitor of dihydrofolate reductase. Dose escalation ranged from 10 to 250 mg/m2/day × 5 days and courses of treatment were repeated every 2‐3 weeks. Biologic effects were observed mostly at doses > 100 mg/m2/day × 5 days. The patients developed myelosuppression during 19% of the trials. Other types of toxicity were dermatitis in 12 to 30% and stomatitis in 7 to 38% of the trials. Toxicity was directly related to the impairment of the patient's liver function. Two partial responses (in a patient with adenocarcinoma of the lung and a patient with transitional cell carcinoma of the bladder) occurred. BAF is an active new chemotherapeutic agent which deserves further clinical trials in patients with various malignancies.

Original languageEnglish (US)
Pages (from-to)690-694
Number of pages5
Issue number2
StatePublished - Aug 1976

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Phase i studies with baker's antifol (baf) (nsc 139105)'. Together they form a unique fingerprint.

Cite this